Osteosarcoma cell viability

Osteosarcoma cell viability is a phenotypic parameter used in preclinical oncology research to quantify the survival and proliferative capacity of osteosarcoma cells, typically in response to pharmacological intervention. It is not a discrete molecular target such as a receptor or enzyme, but rather a composite biological endpoint reflecting the integrated state of cellular metabolism, structural integrity, and signaling pathways (PubMed, PMID: 25130140). In the context of osteosarcoma—a highly aggressive primary bone malignancy—maintaining cell viability involves the dysregulation of key tumor suppressors like p53 and Rb, as well as the activation of growth-promoting pathways such as PI3K/Akt/mTOR (NIH, National Cancer Institute; Journal of Bone Oncology, 2018). Standard chemotherapeutic agents like Doxorubicin and Cisplatin aim to decrease this viability by inducing lethal DNA damage and apoptosis. Consequently, measuring changes in cell viability using assays like MTT, CCK-8, or ATP bioluminescence serves as a fundamental tool for screening the efficacy of novel drug candidates and understanding mechanisms of chemoresistance in bone cancer (Nature Methods, 2005).

Other names

Osteosarcoma cell proliferationOsteosarcoma cell survivalOS cell viabilityOsteosarcoma cell growth

Therapeutic agents reduce osteosarcoma cell viability through various mechanisms including DNA intercalation and topoisomerase II inhibition (Doxorubicin), formation of DNA cross-links (Cisplatin), inhibition of dihydrofolate reductase (Methotrexate), and DNA alkylation (Ifosfamide), all of which ultimately trigger programmed cell death or senescence (American Cancer Society, 2024; PubMed, PMID: 28697204).